FDA
-
-
-
-
-
-
-
CNS Pharmaceuticals (CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
-
-
-
-
-
-
-
CNS Pharmaceuticals (CNSP) Presents Updated Results from On-Going Study of Berubicin
-
-
-
-
-
-
-
CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
-
-
-
-
-
-
-
CNS Pharmaceuticals (CNSP) Presents Ongoing Berubicin Clinical Trial Design
-
-
-
-
-
-
-
CNS Pharmaceuticals (CNSP) Granted Swiss Approval for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
-
-
-
-
-
-
-
CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
-
249,535 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All